Integrated CRDMO from early discovery to commercial supply
Integrated CRDMO from early discovery to commercial supply
Contract Research, Development & Manufacturing Organisation (CRDMO)
Jubilant Biosys Limited, a subsidiary of Jubilant Pharmova Limited, is an integrated CRDMO delivering end‑to‑end drug discovery, development, and manufacturing services across small molecules and emerging modalities. The company supports innovative pharma and biotech companies globally, taking programs from early discovery through IND‑enabling studies and into clinical and GMP manufacturing, backed by deep scientific expertise, robust quality systems, and scalable infrastructure.
Your CRDMO Partner in Science
- End‑to‑end CRDMO platform spanning integrated drug discovery, development, and manufacturing
- 2,400+ professionals, including 1,300+ scientists across India and Europe
- 20+ years of experience supporting discovery, IND‑enabling, and GMP programs
- Five-site presence across India and France, with global commercial presence
- Serving 350+ customers, spanning biotechs to top‑tier pharma
- Recognized for science‑led problem solving, predictable execution, and customer‑focused delivery
Integrated Drug Discovery (IDD)
Integrated Drug Discovery (IDD) platform covers early discovery through pre-clinical-enabling work. It combines biology, medicinal chemistry, computational sciences, DMPK, pharmacology, and toxicology in a tightly integrated model designed to accelerate high‑quality decision‑making.
- Streamlined discovery process designed to achieve rapid milestones
- 100+ integrated programs delivered across several therapeutic areas
- Rapid DMTA cycles, enabled by co-located teams and automated, high-throughput DMPK
- Full coverage from target identification to preclinical candidate selection
- Toxicology support for IND-enabling pathways
Chemistry services
Chemistry platform delivers discovery‑through‑development chemistry supported by deep technical expertise, modern infrastructure, and scalable processes.
- 700+ chemists across six Centers of Excellence in Chemistry
- Expertise across medicinal, synthetic, analytical, and computational chemistry
- Proven capabilities in degraders, peptides, lipids, carbohydrates, photoredox, and complex heterocycles
- Seamless progression from mg‑scale to multi‑kg non‑GMP scale‑up
- Strong integration with biology, DMPK, and CMC to enable informed, hypothesis‑driven design
- Adoption of new and advanced technologies to improve efficiency and sustainability
Biologics and new modalities
Jubilant Biosys has built differentiated capabilities in biologics and advanced modalities, enabling integrated discovery programs beyond traditional small molecules.
- Extensive experience in antibodies and ADCs through our Center of Excellence in St. Julien, France
- Robust biologics discovery capabilities including mAbs, ADCs, oligonucleotides, and peptides
- Several biologics and ADC assets advanced to the clinic across oncology and immuno‑oncology
- In‑house capabilities spanning antibody engineering, linker chemistry, conjugation, analytics, and in‑vitro/in‑vivo biology
- Integrated operating model aligned with small‑molecule IDD to support multi‑modality portfolios
Development and GMP manufacturing
Development and GMP manufacturing platform enables reliable progression from discovery into clinical and commercial supply, supported by strong CMC, quality, and regulatory systems.
- US FDA, EMA, PMDA, ANVISA‑inspected manufacturing site in Nanjangud, India
- 900+ MT annual production capacity with batch sizes ranging from 1 kg to 850 kg
- Seamless tech-transfer, robust supply-chain and back-integration approach
- 97 active DMFs supporting global regulatory filings
- Integrated PR&D, scale‑up, and GMP manufacturing, enabling right‑first‑time tech transfer
- Embedded EHS, quality, and data‑integrity systems ensuring compliance and reliability at scale
